Clinical

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib.

This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions.

Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.

It may be possible to detect Richter transformation (RT) years before it actually occurs in patients with chronic or small lymphocytic leukemia, research indicates.

Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy.

Experts at the 2026 AAD Annual Meeting noted that, together, PCP support, community outreach, and teledermatology help reduce care gaps.

Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis.

Experts at the 2026 AAD Annual Meeting explained that teledermatology helps dermatologists manage their workload and expand patient access beyond traditional in-person care.

Adjuvant pembrolizumab maintained recurrence-free survival in resected stage IIB/IIC melanoma without increasing new melanoma risk.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

Ruxolitinib cream can meaningfully improve skin repigmentation and QOL for patients with vitiligo, but its full benefit depends on improved patient education, guidance, and support for consistent, long-term use.

The study covers the period of 2015-2019 in Germany, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of less toxic BTK inhibitors.

Interim data from the EPCORE-NHL-6 trial show safety outcomes similar to those in the pivotal trial that led to approval for the bispecific T-cell–engaging antibody.

Updated guidelines for CSCC introduce more granular risk stratification and emphasize deeper biopsies to improve staging accuracy and guide decisions about surgery and systemic therapy.

NCCN guideline updates for CSCC emphasize immunotherapy as a cornerstone across disease stages, expanding its role from advanced disease into neoadjuvant and adjuvant settings.

Immunotherapy-related skin adverse events may correlate with improved tumor response and survival, underlining their clinical significance.

This year's meeting in Denver, Colorado, features more than 275 sessions, including 40 new offerings, and a fireside chat with EGOT winner John Legend.

The authors assess use of the novel assistant physician (AP) pathway and examine Missouri regulatory changes. They find limited supply impacts of APs and discuss implications.

Christopher Shade, PhD, shares insights for managed care leaders on oral peptide therapies.

Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.

Subcutaneous amivantamab offers faster treatment, fewer infusion reactions, and improved convenience for patients with EGFR-mutated NSCLC, says Estelamari Rodriguez, MD, MPH.

Insulin affordability improved for Medicare Part D beneficiaries between 2019 and 2023, with more paying $35 or less for a 30-day supply.

This study assessed the impact of hyperpolypharmacy on hospital readmission risk in 2 Medicare populations and identified effects of postdischarge ambulatory care.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.